Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Salt Lake City, Utah

Phase 1 cancer trials in Salt Lake City, UT

59 Phase 1 cancer studies are recruiting participants at sites in Salt Lake City as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Salt Lake City at a glance

  • 59 studies are recruiting at a site in Salt Lake City.
  • By phase: Early Phase 1 (2), Phase 1 (26), Phase 1/2 (31).
  • By sponsor: industry (41), university, hospital or other (16), government (2).
  • By research area: Lymphoma (26), Breast Cancer (13), Lung Cancer (12), Pancreatic Cancer (3), Prostate Cancer (3), Melanoma (2).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Salt Lake City

Basic details from each study's public record (the 30 most recently updated of 59). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Aktis Oncology, Inc.
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT07020117 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Huntsman Cancer Institute University of Utah
    Registry record
    NCT07488676 · updated
  3. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 19 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Intermountain Health
    Registry record
    NCT06586957 · updated
  4. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of Utah - Huntsman Cancer Institute
    Registry record
    NCT06465069 · updated
  5. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    LigaChem Biosciences, Inc.
    Study site
    Intermountain/LDS Hospital Ph 1 Research Program
    Registry record
    NCT06774963 · updated
  6. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT06330064 · updated
  7. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    University of Utah Huntsman Cancer Institute
    Registry record
    NCT07100106 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Lung cancer studies recruiting in Salt Lake City

  1. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT07458347 · updated
  2. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT07020221 · updated
  3. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    University of Utah - Huntsman Cancer Institute
    Registry record
    NCT07542704 · updated
  4. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    University of Utah - Huntsman Cancer Institute - PPDS
    Registry record
    NCT06043817 · updated
  5. Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Huntsman Cancer Institute /ID# 271686
    Registry record
    NCT06772623 · updated
  6. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tango Therapeutics, Inc.
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT06922591 · updated
  7. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tango Therapeutics, Inc.
    Study site
    University of Utah, Huntsman Cancer Institute
    Registry record
    NCT06810544 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Prostate cancer studies recruiting in Salt Lake City

  1. TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT07190300 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Melanoma studies recruiting in Salt Lake City

  1. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT05896839 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Lymphoma studies recruiting in Salt Lake City

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Primary Children's Hospital
    Registry record
    NCT04726241 · updated
  2. A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Debiopharm International SA
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT05765812 · updated
  3. Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Abramson Cancer Center at Penn Medicine
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT07478848 · updated
  4. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Primary Children's Hospital
    Registry record
    NCT06173518 · updated
  5. TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    • Phase 1/2
    • Up to age 1
    • All sexes
    Sponsor
    Tanja Andrea Gruber
    Study site
    University of Utah Huntsman Cancer Institute
    Registry record
    NCT05848687 · updated
  6. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Huntsman Cancer Institute at The University of Utah
    Registry record
    NCT05091424 · updated
  7. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Intermountain - Primary Children's Hospital ( Site 1014)
    Registry record
    NCT06395103 · updated
  8. A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AIDS Malignancy Consortium
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT04139304 · updated
  9. Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

    • Phase 1/2
    • Ages 18 to 80
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT05861050 · updated
  10. Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT06860594 · updated
  11. CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Curis, Inc.
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT03328078 · updated
  12. T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Estrella Immunopharma, Inc.
    Study site
    Intermountain Health, Canyons Region, LDS Hospital
    Registry record
    NCT06343311 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Salt Lake City

  1. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    RayzeBio, Inc.
    Registry record
    NCT07165132 · updated
  2. JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Jacobio Pharmaceuticals Co., Ltd.
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT06973564 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Ask about studies near Salt Lake City

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Utah

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call